Revised SPC: Tybost (cobicistat) 150mg film coated tablet
SPC has been revised to warn treatment with cobicistat (CB) and atazanavir (AT) or darunavir (DN) during 2nd and 3rd trimesters of pregnancy has been shown to result in lower AT or DN exposure compared to postpartum. CB levels decrease and may not provide sufficient boosting.
Source:
electronic Medicines compendium
SPS commentary:
As the substantial reduction in atazanavir or darunavir exposure may result in virological failure and an increased risk of mother to child transmission of HIV infection, therapy with cobicistat and atazanavir or darunavir should not be initiated during pregnancy, and women who become pregnant during therapy with cobicistat and atazanavir or darunavir should be switched to an alternative regimen.